Exact Sciences Statistics
Total Valuation
Exact Sciences has a market cap or net worth of $20.03 billion. The enterprise value is $21.60 billion.
| Market Cap | 20.03B |
| Enterprise Value | 21.60B |
Important Dates
The next estimated earnings date is Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Exact Sciences has 190.89 million shares outstanding. The number of shares has increased by 2.44% in one year.
| Current Share Class | 190.89M |
| Shares Outstanding | 190.89M |
| Shares Change (YoY) | +2.44% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 85.64% |
| Float | 188.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 115.29 |
| PS Ratio | 6.17 |
| Forward PS | 5.33 |
| PB Ratio | 8.34 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 56.13 |
| P/OCF Ratio | 40.75 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 302.23, with an EV/FCF ratio of 60.53.
| EV / Earnings | n/a |
| EV / Sales | 6.65 |
| EV / EBITDA | 302.23 |
| EV / EBIT | n/a |
| EV / FCF | 60.53 |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 1.06.
| Current Ratio | 2.43 |
| Quick Ratio | 1.97 |
| Debt / Equity | 1.06 |
| Debt / EBITDA | 22.34 |
| Debt / FCF | 7.10 |
| Interest Coverage | -3.81 |
Financial Efficiency
Return on equity (ROE) is -8.66% and return on invested capital (ROIC) is -1.86%.
| Return on Equity (ROE) | -8.66% |
| Return on Assets (ROA) | -1.59% |
| Return on Invested Capital (ROIC) | -1.86% |
| Return on Capital Employed (ROCE) | -2.88% |
| Weighted Average Cost of Capital (WACC) | 10.95% |
| Revenue Per Employee | $450,971 |
| Profits Per Employee | -$28,882 |
| Employee Count | 7,200 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 5.99 |
Taxes
In the past 12 months, Exact Sciences has paid $4.06 million in taxes.
| Income Tax | 4.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +129.56% in the last 52 weeks. The beta is 1.44, so Exact Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | +129.56% |
| 50-Day Moving Average | 103.02 |
| 200-Day Moving Average | 74.29 |
| Relative Strength Index (RSI) | 76.40 |
| Average Volume (20 Days) | 3,124,641 |
Short Selling Information
The latest short interest is 7.40 million, so 3.88% of the outstanding shares have been sold short.
| Short Interest | 7.40M |
| Short Previous Month | 7.12M |
| Short % of Shares Out | 3.88% |
| Short % of Float | 3.92% |
| Short Ratio (days to cover) | 3.23 |
Income Statement
In the last 12 months, Exact Sciences had revenue of $3.25 billion and -$207.95 million in losses. Loss per share was -$1.10.
| Revenue | 3.25B |
| Gross Profit | 2.26B |
| Operating Income | -150.12M |
| Pretax Income | -203.89M |
| Net Income | -207.95M |
| EBITDA | 71.46M |
| EBIT | -150.12M |
| Loss Per Share | -$1.10 |
Balance Sheet
The company has $964.71 million in cash and $2.53 billion in debt, with a net cash position of -$1.57 billion or -$8.23 per share.
| Cash & Cash Equivalents | 964.71M |
| Total Debt | 2.53B |
| Net Cash | -1.57B |
| Net Cash Per Share | -$8.23 |
| Equity (Book Value) | 2.40B |
| Book Value Per Share | 12.58 |
| Working Capital | 914.70M |
Cash Flow
In the last 12 months, operating cash flow was $491.44 million and capital expenditures -$134.66 million, giving a free cash flow of $356.78 million.
| Operating Cash Flow | 491.44M |
| Capital Expenditures | -134.66M |
| Depreciation & Amortization | 221.58M |
| Net Borrowing | -249.17M |
| Free Cash Flow | 356.78M |
| FCF Per Share | $1.87 |
Margins
Gross margin is 69.69%, with operating and profit margins of -4.62% and -6.40%.
| Gross Margin | 69.69% |
| Operating Margin | -4.62% |
| Pretax Margin | -6.28% |
| Profit Margin | -6.40% |
| EBITDA Margin | 2.20% |
| EBIT Margin | -4.62% |
| FCF Margin | 10.99% |
Dividends & Yields
Exact Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.44% |
| Shareholder Yield | -2.44% |
| Earnings Yield | -1.04% |
| FCF Yield | 1.78% |
Analyst Forecast
The average price target for Exact Sciences is $86.62, which is -17.43% lower than the current price. The consensus rating is "Hold".
| Price Target | $86.62 |
| Price Target Difference | -17.43% |
| Analyst Consensus | Hold |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 9.99% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exact Sciences has an Altman Z-Score of 1.43 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.43 |
| Piotroski F-Score | 5 |